[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356208-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356208-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","what-are-the-unmet-needs-in-managing-digestive-neuroendocrine-carcinomas-review","What are the Unmet Needs in Managing Digestive Neuroendocrine Carcinomas - Review","","Purpose of Review: This review focuses on the major unmet needs in diagnosing and treating digestive neuroendocrine carcinomas (NEC), and summarizes current and emerging evidence. Recent findings emphasize improved pathological criteria to accurately diagnose NEC and separate it from high-grade well-differentiated neuroendocrine tumors and adenocarcinoma. Evidence gaps persist in selecting patients for surgery, optimizing adjuvant or neoadjuvant therapy, and improving systemic treatment for metastatic disease. Novel approaches, including DLL3 antigen-directed strategies, are evolving, but clinical progress remains limited and prognosis is poor.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/what-are-the-unmet-needs-in-managing-digestive-neuroendocrine-carcinomas-review/356208/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/what-are-the-unmet-needs-in-managing-digestive-neuroendocrine-carcinomas-review/356208.png","ImageObject",300,407,{"name":42,"@type":43},"MrHarris58","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What unmet needs in diagnosis are highlighted for digestive neuroendocrine carcinomas (NEC)?","Question",{"text":63,"@type":64},"The review stresses improved pathological criteria to accurately diagnose NEC and distinguish it from high-grade well-differentiated neuroendocrine tumors (NET G3) and from adenocarcinomas with neuroendocrine differentiation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What evidence gaps exist for treatment in locoregional disease?",{"text":68,"@type":64},"Data are lacking on optimal patient selection for primary tumor surgery and on the role and timing of adjuvant or neoadjuvant treatment for locoregional disease.",{"name":70,"@type":61,"acceptedAnswer":71},"How is metastatic disease systemic treatment described, and what new strategies are emerging?",{"text":72,"@type":64},"Systemic treatment has not improved over the last two decades, and immunotherapy shows limited benefit. Novel antigen-directed strategies targeting DLL3 are evolving.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356208,1790310666,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Current Oncology Reports (2026) 28:95  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1912-026-01833-z  \nREVIEW  \nWhat are the Unmet Needs in Managing Digestive Neuroendocrine Carcinomas?  \nHalfdan Sorbye1,2 · Mairéad G McNamara3 · Margot ET Tesselaar4 · Mauro Cives5,6 · Stian Knappskog1,2 · Aurel Perren7 · Jonathan Strosberg8  \nReceived: 4 September 2026 / Accepted: 10 September 2026 © The Author(s) 2026  \nAbstract  \nPurpose of Review This review highlights the major unmet needs in diagnosis and treatment of digestive neuroendocrine carcinomas (NEC) and describes the current and evolving evidence on these aspects.  \nRecent Findings Improved pathological criteria are needed to accurately diagnose NEC and distinguish this entity from high-grade well-differentiated neuroendocrine tumours as well as from adenocarcinoma. Studies on the molecular mechanisms underlying the extreme aggressiveness of the disease are ongoing. Data are lacking on optimal selection of patients with locoregional disease for primary tumour surgery and use of adjuvant or neoadjuvant treatment. For patients with metastatic disease, there has been no improvement in systemic treatment over the last two decades and immunotherapy has limited benefit. Novel antigen-directed strategies targeting DLL3 are evolving.  \nSummary Digestive NEC are among the most aggressive cancers and prognosis remains poor. There have been only minor improvements over the last two decades. To improve diagnosis and therapy, the unmet needs discussed in this review must be addressed.  \nKeywords Digestive · Neuroendocrine carcinoma · Diagnosis · Treatment  \n Halfdan Sorbye [halfdan.sorbye@helse-bergen.no](halfdan.sorbye@helse-bergen.no)  \n1 Cancer Clinic, Haukeland University Hospital, Bergen, Norway  \n2 Department of Clinical Science, University of Bergen, Bergen, Norway  \n3 Division of Cancer Sciences, Department of Medical Oncology, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK  \n4 Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands  \n5 Interdisciplinary Department of Medicine, University of Bari“Aldo Moro”, Bari, Italy  \n6 Unit of Medical Oncology, AOU Consorziale Policlinico di Bari, Bari, Italy  \n7 Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland  \n8 Department of Gastrointestinal Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA  \nIntroduction  \nDigestive neuroendocrine carcinomas (NEC) are highgrade, aggressive malignancies with a high propensity for early distant metastases and a poor prognosis, even when clinically localised [1–4] . As these are rare cancers, very limited data exist to guide diagnosis and treatment, and therefore there are several major unmet needs. Digestive NEC are frequently misdiagnosed histologically, and better criteria for diagnosing NEC and distinguishing NEC from adenocarcinomas with neuroendocrine differentiation and neuroendocrine tumours grade 3 (NET G3) are needed [5] . The molecular mechanisms behind the extreme aggressiveness of this disease are unknown, but such data are likely needed before major therapeutic improvements can evolve. The use of primary tumour surgery for locoregional disease is highly controversial, and high recurrence rates after surgery have led to recommendations advocating adjuvant and/or neoadjuvant therapy, although definitive evidence is missing [1, 2, 6] . The therapeutic benefit of palliative chemotherapy remains limited, with minimal improvement in clinical outcomes over the past two decades, and  \nimmunotherapy appears to offer only modest additional benefit. Novel therapies are however evolving, such as antigen-directed strategies targeting delta-like ligand-3 (DLL3) .  \nThis review addresses the following major unmet needs for digestive NEC:  \n1. Improving criteria for diagnosing NEC and distinguishing NEC from NET G3 and adenocarcinomas with neuroendocrine differentiation.  \n2.","cbCaicTJQfMMHDMN","https://ap.wps.com/l/cbCaicTJQfMMHDMN","pdf",1359926,12,"English","# Abstract\n# Purpose of Review\n# Recent Findings\n# Summary\n# Keywords\n# Introduction\n## Improving criteria for diagnosis and differentiation\n## Understanding molecular mechanisms behind aggressiveness\n## Role of surgery and perioperative therapy\n## Improving palliative chemotherapy and targeted therapy\n## Use of immune checkpoint inhibitors\n## Role of antigen-directed strategies","[{\"question\":\"What unmet needs in diagnosis are highlighted for digestive neuroendocrine carcinomas (NEC)?\",\"answer\":\"The review stresses improved pathological criteria to accurately diagnose NEC and distinguish it from high-grade well-differentiated neuroendocrine tumors (NET G3) and from adenocarcinomas with neuroendocrine differentiation.\"},{\"question\":\"What evidence gaps exist for treatment in locoregional disease?\",\"answer\":\"Data are lacking on optimal patient selection for primary tumor surgery and on the role and timing of adjuvant or neoadjuvant treatment for locoregional disease.\"},{\"question\":\"How is metastatic disease systemic treatment described, and what new strategies are emerging?\",\"answer\":\"Systemic treatment has not improved over the last two decades, and immunotherapy shows limited benefit. Novel antigen-directed strategies targeting DLL3 are evolving.\"}]","What are the Unmet Needs in Managing Digestive Neuroendocrine Carcinomas - Review | PDF",1790124063,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c583cda9f30ade0d32b7b5c50a1bdc9.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46dbf03dc87f59377deadf595c9c1ddc.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e41dd218cada6ab917a2fb94b3d7977.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d04b1261635172b0e45bd5cf6f3eb8a9.webp",980,1301]